Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatm
To evaluate the Efficacy of a personalized treat-and-extend regimen of faricimab for treatment-naive polypoidal choroidal vasculopathy
| Condition(s) | Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Summary | To evaluate the Efficacy of a personalized treat-and-extend regimen of faricimab for treatment-naive polypoidal choroidal vasculopathy |
| Who can participate | Inclusion Criteria: Potential participants are eligible to be included in the study only if all of the following criteria apply: \[Ocular Conditions\] * Presence of active polypoidal lesions in the macula as shown by Indocyanine green angiography (ICGA) AND presence of serosanguinous maculopathy, i.e., exudative or hemorrhagic features involving the macula on color fundus photography (CFP), FA and spectral domain optical coherence tomography (SD-OCT) AND presence of IRF or SRF that affects the central subfield as seen by SD-OCT. * BCVA score must be ≤ 78 and ≥ 24 letters at 4 meters starting distance using early treatment diabetic retinopathy study (ETDRS) visual acuity charts at both Screening and Baseline. * Greatest liner dimension (GLD) of the total lesion area (branching vascular netw |
| Ages | 50 Years |
| Sex | All |
| Lead sponsor | Yeungnam University College of Medicine |
| Locations | Daegu, Namgu, South Korea |
| Start date | 2026-03-01 |
| NCT ID | NCT07461441 |
| Official listing | https://clinicaltrials.gov/study/NCT07461441 |